Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;106(7):2022-2025.
doi: 10.3324/haematol.2020.270298.

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Adam S Kittai  1 , Scott Best  1 , Bria Thurlow  1 , Vi Lam  1 , Taylor Hashiguchi  1 , Shaun Goodyear  1 , Daniel O Persky  2 , Craig Okada  1 , Byung Park  1 , Stephen E Spurgeon  1 , Alexey V Danilov  3
Affiliations

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Adam S Kittai et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Efficacy of entospletinib and obinutuzumab in patients with chronic lymphocytic leukemia. (A) Redistribution lymphocytosis. Peripheral blood absolute lymphocyte count (ALC) prior to (day -7) and after 7 days of treatment with entospletinib single agent, prior to introduction of obinutuzumab (cycle 1 day 1 [C1D1]). **P<0.01. (B) Nodal response (maximum percent change in the sum of the product [SPD] of the longest perpendicular dimensions) in patients with chronic lymphocytic leukemia evaluable lymphadenopathy. (C) Event-free survival. (D) Duration of treatment.
See this image and copyright information in PMC

References

    1. Mato AR, Nabhan C, Thompson MC, et al. . Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874-879. - PMC - PubMed
    1. Fletcher L, Nabrinsky E, Liu T, et al. . Cell death pathways in lymphoid malignancies. Curr Oncol Rep. 2020;22(1):10. - PubMed
    1. Currie KS, Kropf JE, Lee T, et al. . Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014;57(9):3856-3873. - PubMed
    1. Gobessi S, Laurenti L, Longo PG, et al. . Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. 2009; 23(4):686-697. - PubMed
    1. Paiva C, Rowland TA, Sreekantham B, et al. . SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;102(11):1890-1900. - PMC - PubMed

Publication types

MeSH terms

Substances